DDrare: Database of Drug Development for Rare Diseases

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AF37702 Injection; AF37702, Hematide; Alemtuzumab; Anti-thymocyte globulin; Bortezomib; Bortezomib/dexamethasone; Campath; Campath, Chemo and/or TBI Allo SCT; Cyclophosphamide; Cyclophosphamide + pred; Cyclosporine; Cyclosporine A; Cyclosporine combine with mycophenolate mofetil; Daclizumab; Dexamethasone; Filgrastim; Fludarabine; Fludarabine Phosphate; Hematide; Hematide, peginesatide; Leucine; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Other: Laboratory Biomarker Analysis; Peginesatide; Phosphate; Prednisone; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Peripheral Blood Stem Cell Transplantation; Radiation: Total Body Irradiation; Radiation: Total-Body Irradiation; Rituximab; Sirolimus; Tacrolimus; Trifluoperazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04470804 (ClinicalTrials.gov)	August 1, 2020	9/7/2020	Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study	Pure Red Cell Aplasia, Acquired	Drug: Sirolimus;Drug: Cyclosporine A	Bing Han	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 4	China
2	NCT01288131 (ClinicalTrials.gov)	January 2009	1/2/2011	Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment	Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone	Anti-r-HuEpo Associated PRCA Subjects	Drug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + pred	Chulalongkorn University	NULL	Terminated	18 Years	60 Years	Both	8	Phase 3	Thailand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04470804
(ClinicalTrials.gov)

August 1, 2020

9/7/2020

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study

Pure Red Cell Aplasia, Acquired

Drug: Sirolimus;Drug: Cyclosporine A

Bing Han

NULL

Not yet recruiting

18 Years

70 Years

All

Phase 4

China

NCT01288131
(ClinicalTrials.gov)

January 2009

1/2/2011

Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone

Anti-r-HuEpo Associated PRCA Subjects

Drug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + pred

Chulalongkorn University

NULL

Terminated

18 Years

60 Years

Both

Phase 3

Thailand